Akero Therapeutics, a clinical-stage company based in South San Francisco, California, is dedicated to developing innovative treatments for patients with serious metabolic diseases that have high unmet medical needs. The company recently announced that its management will be presenting at the BofA Securities 2024 Health Care Conference on May 14, 2024, at 5:00 p.m. Pacific Time in Las Vegas, Nevada. Those interested can tune into a live webcast of the presentation on the investor relations section of Akero Therapeutics’ website, [www.akerotx.com](http://www.akerotx.com). An archived replay will also be available on the website for those who miss the live broadcast.
Akero Therapeutics is currently focusing on developing treatments for metabolic diseases such as MASH (Metabolic Associated Fatty Liver Disease), which affects millions of people worldwide and has limited treatment options. The company’s lead product candidate, EFX, is undergoing evaluation in several clinical trials including SYMMETRY study, a Phase 2b trial lasting 96 weeks for patients with compensated cirrhosis due to MASH (F4 fibrosis). Additionally, Akero Therapeutics has two ongoing Phase 3 clinical trials: SYNCHRONY Histology study for patients with pre-cirrhotic MASH (F2-F3 fibrosis) and SYNCHRONY Real-World study for patients with MASH (F1-F3 fibrosis) or MASLD (Metabolic Associated Steatohepatitis and Diabetes). Another Phase 3 clinical trial, the SYNCHRONY Outcomes study for patients with compensated cirrhosis due to MASH (F4 fibrosis), is scheduled to begin in the second quarter of 2024. These studies build upon the positive results of previous Phase 2b clinical trials such as HARMONY and SYMMETRY studies.
For investors looking to get in touch with Akero Therapeutics, they can reach out to Christina Tartaglia of Stern Investor Relations Inc at [(212)362-1200](ntouch://call/S0 “Call Christina Tartaglia using Sorenson VRS”) or [christina@sternir.com](mailto:christina@sternir.com). For media inquiries, Sarah O’Connell can be contacted at [(732)456-0092](ntouch://call/S1 “Call Sarah O’Connell using Sorenson VRS”) or [soconnell@vergescientific